Payment overview · 2025
General Payments
$691.43
44 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher D Schmidt, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · TERRE HAUTE, IN · NPI 1881005213
Verified facts
What the public records show
CMS Open Payments records show Christopher D Schmidt, PA received $691.43 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.18 | 22.3% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.94 | 21.5% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.05 | 19.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.71 | 6.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $37.35 | 5.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.12 | 4.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.22 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.54 | 3.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.88 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.79 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.75 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.03 | 2.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.87 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $691.43 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $137.05 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $122.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.78 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $120.19 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.16 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.16 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.46 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $9.29 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $7.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 462 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 98 |
| Gabapentin | Gabapentin | 360 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 99 |
| Lisinopril | Lisinopril | 310 | 81 |
| Omeprazole | Omeprazole | 301 | 96 |
| Metformin Hcl | Metformin Hcl | 264 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 61 |
| Furosemide | Furosemide | 156 | 55 |
| Famotidine | Famotidine | 148 | 44 |
| Glipizide | Glipizide | 147 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 49 |
| Alprazolam | Alprazolam | 141 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 55 |
| Ozempic | Semaglutide | 137 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 39 |
| Losartan Potassium | Losartan Potassium | 123 | 39 |
| Trazodone Hcl | Trazodone Hcl | 119 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 34 |
| Sertraline Hcl | Sertraline Hcl | 111 | 27 |
| Montelukast Sodium | Montelukast Sodium | 104 | 23 |
| Jardiance | Empagliflozin | 97 | 27 |
| Azithromycin | Azithromycin | 95 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 31 |
| Carvedilol | Carvedilol | 90 | 28 |
| Bupropion Xl | Bupropion Hcl | 88 | 23 |
| Clonazepam | Clonazepam | 86 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 27 |
| Meloxicam | Meloxicam | 85 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 16 |
| Simvastatin | Simvastatin | 81 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 18 |
| Eliquis | Apixaban | 80 | 16 |
| Methylprednisolone | Methylprednisolone | 80 | 64 |
| Allopurinol | Allopurinol | 79 | 26 |
| Prednisone | Prednisone | 79 | 62 |
| Lorazepam | Lorazepam | 78 | 17 |
| Tramadol Hcl | Tramadol Hcl | 78 | 48 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 75 | 53 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 65 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 22 |
| Alendronate Sodium | Alendronate Sodium | 69 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 17 |
| Mounjaro | Tirzepatide | 69 | 12 |
| Buspirone Hcl | Buspirone Hcl | 68 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 12 |
| Trulicity | Dulaglutide | 62 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 22 |
| Cephalexin | Cephalexin | 58 | 51 |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 12 |
| Farxiga | Dapagliflozin Propanediol | 49 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 26 |
| Ezetimibe | Ezetimibe | 47 | 16 |
| Methocarbamol | Methocarbamol | 47 | 15 |
| Potassium Chloride | Potassium Chloride | 47 | 22 |
| Fluconazole | Fluconazole | 46 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 19 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 28 |
| Aripiprazole | Aripiprazole | 40 | 12 |
| Levofloxacin | Levofloxacin | 40 | 31 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 15 |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Valsartan | Valsartan | 33 | 11 |
| Celecoxib | Celecoxib | 32 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 20 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Naproxen | Naproxen | 23 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 19 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 16 |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Mupirocin | Mupirocin | 15 | 14 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $691.43 · 44 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, Cologuard Collection Kit, ENTRESTO, FARXIGA, Kerendia, LEQVIO, LINZESS, MOUNJARO, Ozempic, PAXLOVID, PENMENVY, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error